B
oth peripheral arterial disease (PAD) and chronic kidney disease (CKD) are prevalent in the general population, especially in patients who are older than 65 yr and have other cardiovascular risk factors. The data from the Third National Health and Nutrition Examination Survey (NHANES III) suggest that there are more than 8 million people in the United States with reduced kidney function (defined by a GFR Ͻ60 ml/min per 1.73 m 2 ) (1). PAD is a common disease with a prevalence rate of 14.5% among those aged Ն70 yr and affects approximately 5 million adults aged Ն40 yr in the United States (2) .
According to recent reports, even mild to moderate CKD is a powerful independent predictor of cardiovascular mortality and all-cause mortality (3) (4) (5) (6) (7) (8) (9) . Despite the current recommendation for regular laboratory testing for serum creatinine in patients who are at increased risk for CKD (elderly, those with diabetes, and those with cardiovascular disease [CVD] or other CVD risk factors), the frequency of testing is still significantly low and therefore results in underdetection (10) . Moreover, patients with CKD are at an increased risk for cardiovascular events and mortality yet often receive inadequate disease prevention and management (11) (12) (13) .
Like CKD, PAD is underdiagnosed and undertreated in the general population (14, 15 ). An ankle-brachial index (ABI) cutoff of Ͻ0.9 not only has been shown to be a good screening tool for PAD (90% sensitivity and 98% specificity) (14, 16) but is also associated with increased cardiovascular and all-cause mortality (17) (18) (19) (20) .
PAD is very common in the CKD population (GFR Ͻ60 ml/min) with prevalence rates of 24 to 37% (21) (22) (23) . Both CKD and PAD share the same cardiovascular risk factors and are clinical manifestations of diffuse atherosclerosis. Patients with PAD and ESRD have increased mortality and morbidity. These individuals may present with critical limb ischemia, which is associated with lower successful revascularization rates and higher mortality (24 -27) ; however, the mortality data on PAD in the earlier stages of CKD is still limited. One recent study by O'Hare et al. (28) reported that moderate to severe predialysis CKD significantly increases mortality in patients with advanced PAD; however, that study was limited by its short follow-up (1 yr) and that the PAD population contained only those with advanced PAD (rest pain, ischemic ulceration, or gangrene). In this study, we hypothesized that the risk for death is higher in patients with both CKD and PAD than in those with CKD or PAD alone.
Materials and Methods

Study Population and Measurements
This study was approved by the institutional review board of Cleveland Clinic. Data collected from Cleveland Clinic's electronic record system were supplemented with information from chart review and the Cleveland Clinic's vascular laboratory database (2596 patients whose ABI was recorded in 1999). We selected patients (n ϭ 1079) who had at least one serum creatinine measured within 90 d of an ABI (approximately 67% of patients had two serum creatinine values recorded; CKD status did not differ between before and after measures; P ϭ 0.81). GFR was estimated (eGFR) by adjusting serum creatinine levels for age, gender, and race using the The ABI was calculated by taking the ratio of the highest systolic BP (SBP) measured at the posterior tibial and dorsalis pedis arteries to the highest SBP of the brachial arteries. Of the two ABI measurements for each patient, we selected the lower ABI for study use.
The following baseline demographics were obtained from the Cleveland Clinic computer database system: Age, gender, race (black versus nonblack), history of diabetes, CVD (defined as known history of coronary artery disease [myocardial infarction, angina, coronary artery bypass surgery, or coronary angioplasty], congestive heart failure, PAD, or stroke), hypercholesterolemia and smoking, and number of contrast exposure(s), which includes any angiographic procedures or computed tomographic scan with intravenous contrast. The baseline SBP was obtained from the vascular laboratory database.
The eGFR was categorized into eGFR Ն60 ml/min per 1.73 m 2 (no CKD) versus eGFR Ͻ60 ml/min per 1.73 m 2 (CKD), and the ABI was categorized into ABI Ն0.9 (no PAD) versus ABI Ͻ0.9 (PAD). The patients were categorized according to their CKD and PAD status into four groups: CKD and PAD (eGFR Ͻ60 ml/min per 1.73 m 2 ϩ ABI Ͻ0.9), CKD alone (eGFR Ͻ60 ml/min per 1.73 m 2 ϩ ABI Ն0.9), PAD alone (eGFR Ն60 ml/min per 1.73 m 2 ϩ ABI Ͻ0.9), or no CKD or PAD (eGFR Ն60 ml/min per 1.73 m 2 ϩ ABI Ն0.9).
In addition, the CKD or PAD severity was further categorized according to the levels of ABI and eGFR. Mild PAD was defined as an ABI of 0.7 to 0.89, moderate PAD as an ABI 0.4 to 0.69, and severe PAD as an ABI Ͻ0.4 or calcified arteries in which an ABI value could not be obtained (these patients were classified as severe PAD on the basis of tracings). Mild CKD was defined as an eGFR of 45 to 59.9 ml/min per 1.73 m 2 , moderate CKD as an eGFR of 30 to 44.9 ml/min per 1.73 m 2 , and severe CKD as an eGFR of 15 to 29.9 ml/min per 1.73 m 2 .
Mortality Assessments
Patients were matched with mortality information from the Social Security Death Index. When a patient was not found in the death index, he or she was assumed to be alive as of November 1, 2005 . The Social Security Death Index is extracted from the records at the Social Security Administration that are updated monthly. The death record of the Social Security Administration is reliable and comparable to that of the National Death Index, but some reports of death may be delayed up to 6 mo, which we accounted for in this study by collecting the death data 6 mo after November 2005. When a Social Security number was not recorded for a patient, he or she was censored at the time from their 1999 ABI and eGFR records to their last live visit to the Cleveland Clinic.
Statistical Analyses
The four groups were compared on the basis of continuous baseline measures with ANOVA and of categorical baseline measures with 2 tests. The Kaplan-Meier method was used to plot the probability of survival over time by the four groups, and a log-rank test was used to test for differences between groups.
Logistic regression was used to estimate the independent effects of CKD, PAD, or their combination on risk for death while adjusting for baseline age, race, gender, SBP, history of diabetes, CVD, hypercholesterolemia, and smoking. All tests were two-tailed, and P values were considered statistically significant at the 5% level; SAS 9.1 software (SAS Institute, Cary, NC) was used for all analyses. 
Results
This study cohort consisted of 80% white patients, 18% black patients, and one third patients with diabetes. The percentage of black patients seemed to be higher in the combined CKD and PAD group and PAD alone group than in the other two groups (Table 1) . We found that patients with combined CKD and PAD were more likely to be older and have diabetes and a history of CVD than those with single disease or those without CKD or PAD (Table 1) . Black race was not associated with higher mortality, whereas diabetes was associated with 1.6-fold higher mortality in the multivariate model. Our findings showed that the number of contrast exposures was similar in each subgroup of patients (Table 1) , and the number of contrast exposures did not affect the overall mortality.
Most patients with CKD had mild disease (50%), and there was no difference in the distribution of CKD severity between CKD alone group and the combined CKD and PAD group ( Figure 1A ). Most patients with PAD had moderate disease (46%), and there was no difference in the distribution of PAD severity between the PAD alone group and the combined CKD and PAD group ( Figure 1B) .
The overall 6-yr mortality rate was 28% (284 of 1027 Figure 2 ). The total number of patients censored during the 6-yr period was 133: 23 in the CKD and PAD group, 19 in the CKD alone group, 45 in the PAD alone group and, 46 in the no CKD or PAD group. The Kaplan-Meier analysis showed a greater probability of death for patients with both CKD and PAD compared with the other three groups (Figure 3 ). This is confirmed by the logistic regression model (Table 2) , in which patients with combined CKD and PAD had an approximately four-fold increase risk for death compared with the no disease group and nearly a two-fold increased risk for death compared with the single disease groups. After adjustment for demographic and clinical characteristics, the risk for death for the combined disease group remained significantly higher than that in the other three groups (no CKD or PAD: odds ratio [OR] 2.4 [95% confidence interval (CI) 1.5 to 3.7; P Ͻ 0.001]; CKD alone: OR 2 [95% CI 1.2 to 3.4; P ϭ 0.01]; PAD alone: OR 1.8 [95% CI 1.2 to 2.7; P ϭ 0.002]; Table 2 ).
Discussion
Our findings indicate that patients with both CKD and PAD have a significantly higher risk for death than patients with either disease alone. This increased risk for death persists after adjustment for traditional cardiovascular risk factors. Our study demonstrates an important new caveat in the patient cohort with both CKD and PAD, in which the mortality rate is extremely high even at mild to moderate stages of the diseases.
The increased mortality risk demonstrated in our patients with both CKD and PAD when compared with either disease alone is not accounted for by the difference in the distribution of CKD or PAD severity. This increased risk suggests that there may be additional, unknown mechanisms involved in both diseases (or either disease) that may compound accelerated progression of one or the other over time. This accelerated progression was previously reported by O'Hare et al. (30) , who noted that the presence of PAD predicted the worsening in renal function over time. One possibility is that these two diseases share not only traditional cardiovascular risk factors but also nontraditional risk factors, such as increased inflammatory markers, increased lipoprotein(a) levels, and hyperhomocysteinemia, which may have contributed to accelerated atherosclerosis in this patient cohort (31) (32) (33) (34) (35) (36) . Unfortunately, the exact mechanisms that contribute to increased mortality in this population and hence optimal interventions in this group of patients are still unknown.
An eGFR Ͻ60 ml/min was used in this study as the cutoff for CKD on the basis of the NHANES III definition, which was previously shown to be an independent predictor of mortality in a study of 1 million people (8) . We excluded from our study patients with an eGFR Ͻ15 ml/min per 1.73 m 2 because this group of patients constitutes a minority of the CKD population, and most patients with CKD die of CVD before they develop ESRD (37, 38) ; therefore, we believe that the target population for intervention on the basis of this study should be individuals with mild to moderate CKD, who have not yet reached ESRD.
The main strength of this study is the use of the combination of two sensitive and inexpensive measurement tools for disease definition and detection. We used eGFR as a measurement of renal function because the serum creatinine is not as sensitive a marker for renal function, especially in the elderly (29) . In addition, the MDRD equation has proved to provide a better estimate of renal function than the Cockcroft-Gault formula for patients with known CKD, especially those with diabetes (29, 39) , and all creatinine measurements for this study were calibrated to the MDRD reference laboratory (the Cleveland Clinic renal laboratory). The ABI is sensitive and specific for PAD. It is a simple, affordable, noninvasive test that can be easily performed by the use of a handheld Doppler in the primary care setting by a nurse or a medical assistant.
There are several limitations to this study. First, there is a selection bias of the study because we used the vascular laboratory database as our patient selection resource and selected only individuals who had ABI and serum creatinine performed within 90 d of each other. Second, these study results applied to predominantly white patients who had multiple comorbidities and high coexisting cardiovascular risk factors and were referred to a tertiary hospital and hence had a higher mortality risk than the general population even in the no CKD or PAD group; however, this study has a good representation of patients with diabetes, black race, and female gender. Third, because of the observational nature of this study, a nondirectional misclassification of comorbidities is bound to occur, and residual confounding is always a concern; however, this study did find an association between the combination of CKD and PAD with mortality, which indicates a need for further study to illustrate the mechanisms of these combined diseases on mortality.
Conclusions
Despite competing CVD risk factors, our study demonstrated that patients with both CKD and PAD have a significantly higher mortality risk than patients with either disease alone. This underscores the importance of interventions to reduce mortality risk and future studies to understand better the mechanisms responsible for the relationship between the combined disease processes and the apparent increased mortality risk. Because tests for identifying patients with CKD and PAD (ABI and eGFR) are simple, noninvasive, inexpensive, and practical for the primary care setting, we recommend that health management teams use these tests for all patients with either CKD or PAD at the time of initial diagnosis. 
